04:32 PM EDT, 04/15/2026 (MT Newswires) -- Nkarta ( NKTX ) said late Wednesday it has reached an agreement with the US Food and Drug Administration on key changes to the Ntrust-1 and Ntrust-2 clinical trials in autoimmune disease.

The changes include alleviating the need for overnight stays, allowing outpatient administration of its drug candidate, NKX019, by community research centers and rheumatologists, Nkarta ( NKTX ) said.